Drug Trial Radar · NCT03544723
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
Last checked: Nov 20, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 1, 2018
Primary completion
Jun 30, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- MultiVir, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers. Comparison will be made to historical data. General safety and efficacy using RECIST 1.1 and Immune-Related Response Criteria as well as ECOG performance will be utilized.
Conditions
- Solid Tumor
- Lymphoma
Interventions
Ad-p53Drug
Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint is objective response rate (ORR)Time frame: Change in tumor size at the end of Cycle 2 (each cycle is 28 days)
- Safety assessments of adverse events per CTCAETime frame: Signed Informed Consent through 30 Days following the final treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Robert H. Lurie Comprehensive Cancer Center | Northwestern University
Chicago, Illinois · Recruiting
Rush University Cancer Center
Chicago, Illinois · Recruiting
Morristown Medical Center
Morristown, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.